A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and NabPaclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
Study of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Pancreatic Cancer
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAU6715
U.S. Govt. ID: NCT05685602
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety of a drug called CA-4948 in combination with gemcitabine and nab-paclitaxel. This study tests different doses of the drug CA-4948 to see which dose is safer for people. There will be about 36 people taking part in this study. CA-4948 is not approved by the FDA for treatment of pancreatic cancer.
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have pancreatic cancer which has progressed after previous chemotherapy treatment? Yes No
Are you able to make extra visits to the clinic for treatment and assessments? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE